Press Release – For immediate release – April 25, 2017 – 17:45 CEST –
Median Technologies (ALMDT:PA), the Imaging Phenomics Company™, today announces that it has been awarded the 2017 Tech 40 Label, and is now included in the EnterNext Tech 40 Index.
The Tech 40 Label is an initiative launched by EnterNext in 2015 and spotlights the 40 top-performing European companies in the Tech sector (i.e., Biotech and Medtech, Cleantech and Technology-Media-Telecom companies) listed on the Euronext markets in Paris, Amsterdam, Brussels and Lisbon.
The Tech 40 Label is awarded each year to the top 40 of the 330 Tech companies listed on the Euronext by a committee of independent European experts based on business, financial, and stock market performance criteria.
Median Technologies is listed on Alternext Euronext Paris since May 2011. Its iBiopsy® platform is revolutionizing personalized medicine through the use of advanced imaging phenomics that enable the detection, diagnosis, and monitoring of disease evolution as well as provide insights into novel drug therapy development and treatment strategies for patients.
The Tech 40 Label denotes Median Technologies as a high potential innovative company among Tech companies, and will enhance its visibility among international investors.
For more information about the Tech 40 companies click: https://tech.euronext.com/en/our-tech-companies/all-tech-40-companies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.
